580 California St., Suite 400
San Francisco, CA, 94104
Key research themes
1. How does the regulation of BCL-2 gene expression at transcriptional and post-translational levels affect apoptotic pathways in cancer progression and therapy resistance?
This research theme focuses on the molecular regulation of BCL-2 gene and protein expression, encompassing transcriptional control, post-translational modifications such as phosphorylation, and their impacts on apoptosis modulation. Understanding these regulatory mechanisms is critical because aberrant BCL-2 expression frequently causes evasion of programmed cell death in cancer, contributing to tumorigenesis and resistance to treatments. Insights into these processes provide foundational knowledge for designing agents that can restore apoptosis in malignant cells.
Key finding: This review delineates the stringent multi-layered control of BCL-2 family protein expression, including transcriptional, post-transcriptional, and post-translational mechanisms, regulating the intrinsic apoptotic pathway. It... Read more
Key finding: By precisely identifying Ser87 and Thr56 as phosphorylation sites on Bcl-2 mediated by p38 MAPK, this study demonstrates that such phosphorylation diminishes Bcl-2’s anti-apoptotic potential. Functional experiments revealed... Read more
Key finding: This comprehensive review reports that the BCL-2 gene is located at chromosomal locus 18q21.33 and its overexpression in cancers is often caused by t(14;18) chromosomal translocation leading to deregulated transcription under... Read more
2. What are the therapeutic implications of targeting BCL-2 family proteins, including development of BH3 mimetics, in overcoming apoptosis resistance in cancer treatments?
This area investigates small molecule inhibitors and peptide mimetics (BH3 mimetics) that emulate pro-apoptotic BH3-only proteins binding selectively to pro-survival BCL-2 family members to release pro-apoptotic effectors like BAX/BAK, thereby restoring apoptosis in cancer cells. Understanding selective inhibition profiles, resistance mechanisms, and clinical efficacy is essential for advancing targeted therapies that potentiate cancer treatment, particularly in hematologic malignancies and solid tumors.
Key finding: This article consolidates evidence that BH3 mimetic compounds, which mimic BH3-only protein domains, selectively bind and inhibit pro-survival BCL-2 family proteins (e.g., BCL-2, BCL-X L, MCL-1), thus freeing pro-apoptotic... Read more
Key finding: Through lineage-specific Bcl-2 deletion and selective BH3 mimetic inhibition, this study elucidates that BCL-2 is not essential for megakaryocyte development or platelet survival, whereas BCL-X L is critical. The findings... Read more
Key finding: This review advances recent structural and functional insights into BAX/BAK activation and anti-apoptotic BCL-2 regulation, underscoring molecular interactions critical for mitochondrial outer membrane permeabilization... Read more
3. How does dysregulated BCL-2 expression impact disease development and prognosis across hematologic and solid tumors, including biomarker relevance?
This theme examines the pathological consequences of aberrant BCL-2 expression, particularly its prognostic value and role in disease phenotypes such as lymphoma, diffuse large B-cell lymphoma (DLBCL), glioblastoma, and various solid tumors. It includes investigations into BCL-2 gene translocations, expression patterns detected by immunohistochemistry or molecular methods, and correlations with clinical outcomes, as well as the interplay with other apoptotic and regulatory genes.
Key finding: Analyzing 456 DLBCL patients treated with R-CHOP, this study proposes validated four-grade scoring criteria for BCL-2 protein expression via immunohistochemistry, correlating strong (3+) expression in ~40% cases with poorer... Read more
Key finding: Employing automated quantitative immunofluorescence (AQUA), this research integrates intensity and proportion measures of BCL-2 expression in 221 DLBCL cases to enhance prognostic accuracy. The findings demonstrate that... Read more
Key finding: This paper further contextualizes BCL2 overexpression due to t(14;18) translocation in follicular lymphoma and its modulation of the intrinsic apoptotic pathway, linking its aberrant activity to lymphoma progression and... Read more
Key finding: This study establishes that BCL6 expression, a transcriptional regulator upstream of apoptosis, is induced by irradiation in glioblastoma, altering proteomic responses relevant to DNA damage and stress signaling. Inhibiting... Read more